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Abstract The acute e¡ect of palmitate on glucose metabolism
in rat skeletal muscle was examined. Soleus muscles from Wis-
tar male rats were incubated in Krebs^Ringer bicarbonate bu¡-
er, for 1 h, in the absence or presence of 10 mU/ml insulin and
0, 50 or 100 WM palmitate. Palmitate increased the insulin-
stimulated [14C]glycogen synthesis, decreased lactate produc-
tion, and did not alter D-[U-14C]glucose decarboxylation and
2-deoxy-D-[2,6-3H]glucose uptake. This fatty acid decreased
the conversion of pyruvate to lactate and [1-14C]pyruvate decar-
boxylation and increased 14CO2 produced from [2-14C]pyruvate.
Palmitate reduced insulin-stimulated phosphorylation of insulin
receptor substrate-1/2, Akt, and p44/42 mitogen-activated pro-
tein kinases. Bromopalmitate, a non-metabolizable analogue of
palmitate, reduced [14C]glycogen synthesis. A strong correlation
was found between [U-14C]palmitate decarboxylation and
[14C]glycogen synthesis (r=0.99). Also, palmitate increased in-
tracellular content of glucose 6-phosphate in the presence of
insulin. These results led us to postulate that palmitate acutely
potentiates insulin-stimulated glycogen synthesis by a mecha-
nism that requires its metabolization (Randle cycle). The inhib-
itory e¡ect of palmitate on insulin-stimulated protein phosphor-
ylation might play an important role for the development of
insulin resistance in conditions of chronic exposure to high levels
of fatty acids.
; 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Increased plasma levels of free fatty acids (FFA) occur in
states of insulin resistance such as type 2 diabetes mellitus and
obesity [1^3]. These high levels of plasma FFA have been
postulated to play an important role for the development of
insulin resistance but the mechanisms involved remain to be
fully established.
In 1963, Randle et al. [4] described the fatty acid^glucose
cycle (the Randle cycle) to explain insulin resistance. These
authors showed that FFA decrease glucose utilization by iso-
lated rat heart and diaphragm. The hypothesis is that in-
creased FFA oxidation enhances the generation of acetyl-
CoA that leads up to increased citrate production through
the Krebs cycle. Citrate, in association with an increase in
the ATP/ADP ratio, inhibits phosphofructokinase, resulting
in reduced glycolytic £ux. As a consequence, there is an in-
crease in the glucose 6-phosphate content, which inhibits
hexokinase II activity, leading to an increase in intracellular
glucose content and a reduction in glucose uptake [4,5]. How-
ever, studies with nuclear magnetic resonance showed that
FFA decrease the glucose and glucose 6-phosphate intracel-
lular content [6,7], suggesting that other mechanisms are in-
volved in the FFA-induced insulin resistance.
FFA a¡ect the activity of insulin signalling proteins in dif-
ferent cell lines and mammal tissues: insulin receptor activity,
insulin receptor substrate-1 (IRS-1) and protein kinase B
(PKB) phosphorylation in pmi 28 cells [8] ; insulin receptor
a⁄nity [9] and glucose transporter-4 (GLUT-4) intrinsic ac-
tivity [10] in adipocytes; mitogen-activated protein (MAP) ki-
nase activity in ¢broblasts [11] ; MAP kinase, phosphatidyl-
inositol 3-kinase (PI3-K) [12], Akt and atypical protein kinase
C (PKC) activities [13] in C2C12 myotubes; and IRS-1 phos-
phorylation, PI3-K activity-associated IRS-1 [14^16], PKB
and atypical PKC activities [17,18], and GLUT-4 transloca-
tion [17,19] in skeletal muscle. These e¡ects were accompanied
by reduced insulin responses such as glucose uptake and gly-
cogen synthesis [8,12^14,17].
Contrary to the information above, other studies suggest
that FFA acutely increase insulin action. Palmitate acutely
raises both basal and insulin-stimulated glucose uptake in
adipocytes [20^22]. Rats subjected to euglycemic-hyperinsuli-
nemic glucose clamp, combined with acute FFA infusion,
show a larger whole body glucose utilization and muscle gly-
cogen synthesis [23]. However, if the FFA infusion is longer
than 2 h, glucose utilization and glycogen synthesis rapidly
decline [24,25]. Thus, the e¡ects of FFA on glucose metabo-
lism and insulin signalling pathways still remain controversial.
In this study the acute e¡ects (up to 1 h) of palmitate on
glucose metabolism and on insulin signalling pathway that
involves phosphorylation of IRS-1/2, Akt, and p44/42 MAP
kinases in incubated rat soleus muscle were investigated.
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2. Materials and methods
2.1. Material
All enzymes and reagents for bu¡ers were obtained from Sigma
Chemical Co. (St. Louis, MO, USA). Regular insulin was obtained
from Biobra¤s (M. Claros, MG, Brazil). D-[U-14C]Glucose, 2-deoxy-D-
[2,6-3H]glucose, [1-14C]- and [2-14C]pyruvate, and ECL Western Blot-
ting System Kit were obtained from Amersham International (Bucks,
UK). [U-14C]Palmitate and L-[1-14C]glucose were obtained from NEN
Life Sciences Products (Boston, MA, USA). Anti-phosphoserine(473)-
Akt and anti-phospho-p44/42 (Thr202/Tyr204) MAP kinase antibod-
ies were obtained from Cell Signaling Technology (Beverly, MA,
USA). Anti-phosphotyrosine and anti-IRS-1 antibodies were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-IgG
polyclonal antibody conjugated to horseradish peroxidase was ob-
tained from ICN Biomedicals (Irvine, CA, USA).
2.2. Animals
Male Wistar rats weighing 140^160 g were obtained from the De-
partment of Physiology and Biophysics, Institute of Biomedical Sci-
ences, University of Sa‹o Paulo. Animals were housed under a 12:12 h
light^dark cycle, at 23Q1‡C. The chow was removed 4 h before the
beginning of the experiment, which was always carried out at 11.00 h.
The study was approved by the Ethical Committee of the Institute of
Biomedical Sciences, University of Sa‹o Paulo.
2.3. E¡ect of palmitate on glucose metabolism in incubated soleus
muscle
Soleus muscles were isolated and incubated as previously described
[26,27]. Rats were killed by cervical dislocation and soleus muscles
were rapidly and carefully isolated, split longitudinally into two equal
portions, weighed (20^30 mg) and pre-incubated for 30 min, at 37‡C,
in Krebs^Ringer bicarbonate bu¡er pre-gassed for 30 min with 95%
O2/5% CO2, containing 5.6 mM glucose, pH 7.4, with agitation at
120 rpm. After this period, the muscles were transferred to other
vials containing the same bu¡er, but supplemented with 0.3 WCi/ml
D-[U-14C]glucose and 0.2 WCi/ml 2-deoxy-D-[2,6-3H]glucose and glu-
cose 5.6 mM. Incubation was then performed for 1 h under similar
conditions, in the absence or presence of 10 mU/ml insulin and 0, 50
or 100 WM palmitate (previously dissolved in ethanol, solution of
palmitate at 20 mM). A high concentration of insulin was used to
pronounce the e¡ect of palmitate. As control, some muscles were in-
cubated in the presence of 0.5% ethanol. Previous experiments had
demonstrated that 0.5% ethanol does not alter the responsiveness to
insulin (data not shown). Measurements of lactate production from
pyruvate (2 mM), [1-14C]- and [2-14C]pyruvate decarboxylation
(0.2 WCi/ml) were also carried out in muscles incubated for 1 h in
the presence of insulin (10 mU/ml) and palmitate (100 WM) and the
results were compared with those of insulin only.
Phenylethylamine (0.3 ml solution 1:1 in methanol) was added into
a separate compartment to measure 14CO2 adsorption. After the
incubation period, the muscles were brie£y washed in saline at 4‡C
and frozen in liquid N2. [14C]Glycogen synthesis (as estimated by
D-[14C]glucose incorporation into glycogen) was determined as de-
scribed by Leighton and Cooper [28]. Lactate production was deter-
mined as described by Engel and Jones [29]. Decarboxylation of
D-[14C]glucose, [1-14C]- and [2-14C]pyruvate and uptake of 2-deoxy-
D-[2,6-3H]glucose were measured as previously described [30^32]. For
determination of the extracellular space, some muscles were incubated
in the presence of 0.1 WCi/ml L-[1-14C]glucose [33]. Total glycogen
content of the muscles was determined as described by Leighton et
al. [34].
2.4. E¡ect of palmitate on insulin signalling proteins
Muscles were incubated for periods of 5, 30 or 60 min in the pres-
ence of 100 WM palmitate. Insulin (10 mU/ml) was added to the
medium and the muscles incubated for 5 min more. This period of
insulin stimulation is su⁄cient to cause maximal phosphorylation of
the proteins studied (data not shown). For comparison, some muscles
were incubated for 5 min in the absence (control group) or presence of
10 mU/ml insulin (insulin group) and others for 30 min in the pres-
ence of 100 WM palmitate only. At the end of the incubation period,
muscles were immediately homogenized in 0.6 ml extraction bu¡er
(100 mM Trizma, pH 7.5; 10 mM EDTA; 10% sodium dodecyl sul-
fate (SDS); 100 mM NaF; 10 mM sodium pyrophosphate; 10 mM
sodium orthovanadate; at 100‡C) for 30 s. Samples were boiled for
5 min and centrifuged at 12 000 rpm, for 40 min, at 4‡C. Aliquots of
supernatants were used for the measurement of total protein content,
as described by Bradford [35]. Equal amounts of proteins of each
sample were separated using 6% SDS^polyacrylamide gel [36]. West-
ern blotting was carried out following the method described by Tow-
bin et al. [37]. The proteins of the gel were transferred to a nitro-
cellulose membrane at 120 V for 1 h. Non-speci¢c bounds were
blocked by incubating the membranes with 5% defatted milk in basal
solution (10 mM Trizma, pH 7.5; 150 mM NaCl; 0.05% Tween 20) at
room temperature, for 2 h. Membranes were washed in basal solution
three times for 10 min each and then incubated with anti-phosphoty-
rosine, anti-IRS-1, anti-phosphoserine(473)-Akt or anti-phospho-p44/
42 MAP kinase antibodies in basal solution containing 3% defatted
milk, at room temperature, for 3 h. Membranes were washed again
(three times for 10 min each) and incubated with anti-IgG antibody
linked to horseradish peroxidase in basal solution containing 1% de-
fatted milk, at room temperature, for 1 h. Following washing again,
membranes were incubated with substrate for peroxidase and chemi-
luminescence enhancer (Amersham Pharmacia Biotech) for 1 min and
immediately exposed to X-ray ¢lm for 1^20 min. Films were then
revealed in the conventional manner.
2.5. E¡ect of bromopalmitate on [14C]glycogen synthesis in incubated
soleus muscle
To verify if the alterations in [14C]glycogen synthesis by palmitate
were due to its metabolization, the non-metabolizable analogue of this
fatty acid, bromopalmitate, was tested at 100 WM. Bromopalmitate
and palmitate compete equivalently for the same ligand binding sites
and tissue-speci¢c transport [38]. Results of in vivo studies demon-
strate bromopalmitate tracer as a valuable tool for the assessment of
tissue-speci¢c total fatty acid uptake [39]. The procedure used was the
same as described for palmitate.
2.6. Correlation between [14C]glycogen synthesis and
[U-14C]palmitate decarboxylation
Muscles were incubated for periods of 15, 30 and 60 min to deter-
mine concomitantly both [14C]glycogen synthesis and [U-14C]pal-
mitate decarboxylation in the presence of 10 mU/ml insulin and
100 WM palmitate. Determination of [14C]glycogen synthesis was car-
ried out as described above [28]. To measure [U-14C]palmitate decar-
boxylation, the fatty acid was added into the incubation medium at
0.2 WCi/ml. The method to determine [U-14C]palmitate decarboxyla-
tion was the same as utilized for D-[U-14C]glucose [30].
2.7. E¡ect of palmitate on intracellular content of glucose 6-phosphate
in incubated soleus muscle
Muscles were incubated for 1 h in the absence or presence of 10 mU/
ml insulin and/or 100 WM palmitate. The muscles were then frozen in
liquid N2 and the glucose 6-phosphate content was determined as
described by Lang and Michal [40].
2.8. Statistical analysis
The data are presented as meanQS.E.M. and analyzed by one-way
ANOVA and Tukey test (P6 0.05). Linear regression analysis was
used to determine the correlation between [14C]glycogen synthesis
and [U-14C]palmitate decarboxylation. Band intensities were quanti-
¢ed by optical densitometry using the Scion Image program (Freder-
ick, MD, USA).
3. Results
3.1. E¡ect of palmitate on glucose metabolism in incubated
soleus muscle
Palmitate itself had no e¡ect on basal glycogen synthesis in
incubated soleus muscle (Fig. 1A). However, the simultaneous
incubation of palmitate at 50 or 100 WM with 10 mU/ml
insulin induced a signi¢cant increase of glycogen synthesis.
The increases were 17% (P6 0.05) and 62% (P6 0.001) at
50 and 100 WM, respectively (Fig. 1A). Total glycogen content
of the muscles was not changed by all treatments imposed.
The mean value at the end of 1 h incubation period was
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25.96Q 0.90, expressed as Wmol per g muscle fresh weight and
presented as meanQS.E.M. of six determinations from two
experiments.
Palmitate 100 WM had no e¡ect on basal lactate production
but it completely abolished the increase of lactate production
induced by insulin at both 50 and 100 WM concentrations
(P6 0.001) (Fig. 1B). Basal glucose decarboxylation was in-
creased by 100 WM palmitate (79%; P6 0.05) (Fig. 1C). In the
presence of 10 mU/ml insulin, this fatty acid led to a slight
increase of this parameter (Fig. 1C). Neither basal nor insulin-
stimulated 2-deoxy-D-glucose uptake was altered by palmitate
(Fig. 1D).
In the presence of insulin, palmitate (100 WM) caused a
signi¢cant (P6 0.05) decrease of the conversion of pyruvate
into lactate (from 10.20Q 0.99 to 5.41Q 0.50), [1-14C]pyruvate
decarboxylation (from 3.34Q 0.21 to 2.52 Q 0.21) and an in-
crease of 14CO2 produced from [2-14C]pyruvate (from
0.75Q 0.05 to 1.10Q 0.05) by soleus muscle incubated for 1 h.
The values are expressed as Wmol/h per mg protein and pre-
sented as meanQS.E.M. of six determinations from two ex-
periments.
3.2. E¡ect of palmitate on insulin-induced protein
phosphorylation
As one should expect, an increase in tyrosine phosphoryla-
tion of a band corresponding to pp185 was obtained by im-
munoblotting of the whole extract after insulin stimulation.
pp185 is known to contain at least two well characterized
proteins, IRS-1 and IRS-2. IRS-1 is the major component
of this band [41,42].
IRS-1 protein level remained unchanged (Fig. 2A) but 100
WM palmitate induced a decrease in insulin-stimulated IRS-1/2
tyrosine phosphorylation already after 5 min incubation (Fig.
2B). In the absence of insulin, palmitate had no e¡ect on this
protein phosphorylation after 5 min incubation (data not
shown). Since stimulation with insulin results in activation
of the PI3-K/Akt [43^45] and MAP kinase pathways [46],
immunoblotting with anti-phosphoserine(473)-Akt and anti-
phospho-p44/42 MAP kinase antibodies was then performed.
Insulin-induced Akt serine phosphorylation was reduced in
isolated muscles incubated with palmitate. The decrease was
39% (P6 0.01) after 5 min and reached 51% (P6 0.001) after
60 min (Fig. 2C). The insulin-induced phosphorylation of p44/
42 MAP kinases was also reduced by palmitate. The reduction
was 64% after 30 min (P6 0.05) and reached 88% after 60
min (P6 0.001) of incubation with palmitate (Fig. 2D).
3.3. Evidence that palmitate metabolization is required to
promote its e¡ect on glycogen synthesis
Bromopalmitate (a non-metabolizable analogue) in contrast
to palmitate reduced insulin-stimulated glycogen synthesis by
27% (P6 0.001) (Fig. 3). The glucose 6-phosphate intracellu-
                  
 
 
 
 
 
 
                      
 
   
 
 
Fig. 1. E¡ect of palmitate (P) on glucose metabolism in soleus muscle. Muscles were incubated in Krebs^Ringer bicarbonate bu¡er, containing
5.6 mM glucose, 0.3 WCi/ml D-[U-14C]glucose, and 0.2 WCi/ml 2-deoxy-D-[2,6-3H]glucose, for 1 h in the absence or presence of 10 mU/ml insulin
(I) and 0, 50 (P50) or 100 (P100) WM palmitate. [14C]Glycogen synthesis (A), lactate production (B), [U-14C]glucose decarboxylation (C) and
2-deoxy-D-[2,6-3H]glucose uptake (D) were determined as described by Leighton and Cooper [28] ; Engel and Jones [29]; Ceddia et al. [30,32],
respectively. Data are presented as meanQS.E.M. (n=24).
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lar content was not altered by palmitate itself (Fig. 4). How-
ever, the simultaneous incubation of 100 WM palmitate with
10 mU/ml insulin induced a signi¢cant increase (by 27%) of
the content of this metabolite as compared with the insulin
group (P6 0.01) (Fig. 4).
To determine if oxidation of palmitate was correlated with
insulin-stimulated glycogen synthesis, both measurements
were carried out concomitantly in soleus muscle incubated
for 15, 30 and 60 min in the presence of 10 mU/ml insulin
and 100 WM palmitate. [14C]Glycogen synthesis and [U-
14C]palmitate decarboxylation were highly correlated:
r2 = 0.99.
4. Discussion
Palmitate increased insulin-stimulated glycogen synthesis
and decreased insulin-stimulated glycolytic £ux (lactate pro-
duction). Incubation in the presence of insulin and palmitate
raised the glucose 6-phosphate content in the muscles (Fig. 4)
as postulated by the Randle cycle [4]. These results, in asso-
ciation with the fact that insulin-stimulated 2-deoxy-D-glucose
uptake was not altered by the fatty acid, suggest that palmi-
tate leads to glucose accumulation as glycogen rather than
being utilized through glycolysis. Palmitate did not inhibit
glucose decarboxylation and instead increased this parameter
bluntly (Fig. 1C). Pyruvate generated from glucose is con-
verted into CO2 through pyruvate dehydrogenase and the
Krebs cycle entering via the pyruvate carboxylase reaction
[31,47]. In order to estimate the contribution of both decar-
boxylation sites (pyruvate dehydrogenase and Krebs cycle),
measurements of 14CO2 production from [1-14C]- and [2-
14C]pyruvate were carried out. [2-14C]Pyruvate is decarboxy-
lated through the tricarboxylic acid cycle only in opposition to
[1-14C]pyruvate, which produces 14CO2 in both sites. In the
presence of insulin, palmitate decreased the production of
14CO2 from [1-14C]pyruvate and enhanced 14CO2 formation
from [2-14C]pyruvate. An increase in acetyl-CoA content from
palmitate oxidation leads to inhibition of pyruvate dehydro-
genase activity, decreasing the conversion of pyruvate to ace-
tyl-CoA, but also enhances pyruvate carboxylase activity,
raising the conversion of pyruvate to oxaloacetate that enters
the Krebs cycle being then oxidized.
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. E¡ect of palmitate (P) on total IRS-1 (A) and on insulin-stimulated phosphorylation of IRS-1/2 (B), Akt (C) and p44/42 MAP kinases
(D) in soleus muscle. Muscles were incubated for 5, 30 or 60 min in the presence of 100 WM palmitate. Insulin (I) was added to the medium at
10 mU/ml and the muscles incubated for 5 min more. Some muscles were incubated for 5 min in the absence (control group) or presence of
10 mU/ml insulin (insulin group) and others for 30 min in the presence of 100 WM palmitate. At the end of the incubation, muscles were ho-
mogenized in extraction bu¡er at 100‡C and centrifuged as described in Section 2. Aliquots of proteins of the muscle lysates (75 Wg) were re-
solved in 6% SDS^polyacrylamide gel and transferred to a nitrocellulose membrane. IRS-1, IRS-1/2 phosphotyrosine, Akt phosphoserine(473)
and phospho-p44/42 MAP kinases were visualized by immunoblotting using speci¢c IRS-1, phosphotyrosine, phosphoserine(473)-Akt and phos-
pho-p44/42 MAP kinase antibodies, respectively. Data are presented as meanQS.E.M. of three experiments (n=6).
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The di¡erences between our studies and those of others [48^
50] may be due to the concentrations of palmitate used. While
the studies that found reduction in insulin actions utilized
supraphysiological concentrations of fatty acids, from 1 to
2.8 mM [48^50], in the present study plasma physiological
concentrations of palmitate were used: 50 and 100 WM.
The e¡ects of palmitate on some of the proteins involved in
the mechanism of action of the hormone were studied. Palmi-
tate reduced insulin-stimulated phosphorylation of IRS-1/2,
Akt, and p44/42 MAP kinases. These results suggest that
the increased insulin-stimulated glycogen synthesis by palmi-
tate is not related to activation of these proteins. Results of
the total IRS-1 suggest that the lower phosphorylation of this
protein induced by the fatty acid was not due to inhibition of
protein synthesis. Whether lower insulin-stimulated IRS-1 ty-
rosine phosphorylation in the presence of palmitate is due to
inhibition of insulin receptor tyrosine kinase activity, in-
creased serine/threonine phosphorylation of IRS-1 or stimu-
lation of phosphotyrosine phosphatase activity remains to be
investigated. These three hypotheses have been associated
with decreased insulin-induced tyrosine phosphorylation in
studies using cultured cells and animal tissues [51^54].
Simoneau et al. [55] observed that increased plasma FFA
levels in humans subjected to euglycemic-hyperinsulinemic
glucose clamp decrease FFA oxidation and increase FFA
storage in skeletal muscle. However, other studies show in-
creased expression of fatty acid metabolism genes in muscle
due to infusion of fatty acids [56]. Bromopalmitate is a com-
petitive inhibitor of carnitine palmitoyltransferase-1 [31,57,58]
and so of FFA oxidation. In opposition to palmitate, bromo-
palmitate reduced insulin-stimulated glycogen synthesis. This
observation associated with the high correlation between in-
creased insulin-stimulated glycogen synthesis and decarboxy-
lation of palmitate and the accumulation of glucose 6-phos-
phate induced by palmitate support the proposition that
palmitate metabolization is required to potentiate insulin-
stimulated glycogen synthesis.
In summary, palmitate acutely increases insulin-stimulated
glycogen synthesis and decreases insulin-stimulated glycolytic
£ux in skeletal muscle by a mechanism that requires its me-
tabolization. These e¡ects may occur through the Randle
cycle. Reduction in the insulin-stimulated phosphorylation
of IRS-1/2, Akt and p44/42 MAP kinases by palmitate does
not decrease insulin-stimulated glycogen synthesis acutely but
it may be involved in the onset of insulin resistance in con-
ditions of chronic exposure to high plasma FFA levels.
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